Triple negative breast cancer (TNBC) continues to be the subtype of breast cancer with the
highest rates of recurrence and mortality. The lack of expression of targetable proteins such …

Breast cancer is the most common cancer worldwide. The occurrence of breast cancer is
associated with many risk factors, including genetic and hereditary predisposition. Breast …

PURPOSE To develop guideline recommendations concerning optimal neoadjuvant therapy
for breast cancer. METHODS ASCO convened an Expert Panel to conduct a systematic …

Background We aimed to report on long-term outcomes of patients with small, node-
negative, HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab and …

PURPOSE APHINITY, at 45 months median follow-up, showed that pertuzumab added to
adjuvant trastuzumab and chemotherapy significantly improved invasive disease–free …

Over the past 2 decades, there has been an extraordinary progress in the regimens
developed for the treatment of human epidermal growth factor receptor 2 (HER2)-positive …

Highlights•Breast cancer in young women should be treated based on stage and biology of
disease.•Management of breast cancer in young women requires special considerations …

Advances in HER2-targeted therapies have improved the survival of patients with HER2-
positive breast cancer. The standard-of-care treatment for localized disease has been …

PURPOSE The ATEMPT trial was designed to determine if treatment with trastuzumab
emtansine (T-DM1) caused less toxicity than paclitaxel plus trastuzumab (TH) and yielded …

PURPOSE The Standardized Definitions for Efficacy End Points (STEEP) criteria,
established in 2007, provide standardized definitions of adjuvant breast cancer clinical trial …